Sort
10,766 grants matching “checkpoint inhibitor”
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas
$1,316,276Xandra Owens Breakefield · Massachusetts General Hospital · P01 · FY2020 · CA
Center for Interventional Oncology
$1,316,258Bradford J Wood · Division Of Basic Sciences - Nci · ZID · FY2021 · CA
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas
$1,316,194Xandra Owens Breakefield · Massachusetts General Hospital · P01 · FY2021 · CA
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
$1,314,469Andrea Califano · Columbia University Health Sciences · U01 · FY2018 · CA
DEFINE THE HUMORAL IMMUNITY IN KIDNEY CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
$1,312,000The University Of Texas Southwestern Medical Center · · FY2024 · Defense Health Agency
Studies of Receptor Interactions and Effects of Alarmins
$1,311,888Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Regulation of innate lymphocyte function
$1,311,736Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
MAP4K3 regulation of cellular stress response pathways in health and disease
$1,310,665Albert R La Spada · University Of California-Irvine · RF1 · FY2025 · AG
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
$1,309,379Naoto T Ueno · University Of Hawaii At Manoa · R01 · FY2025 · CA
Studies of Receptor Interactions and Effects of Alarmins
$1,307,824Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Liver Cancer Program
$1,307,380Anuradha Budhu · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer
$1,306,362Scott McNear Thacher · Orphagen Pharmaceuticals · R44 · FY2021 · CA
Unraveling the Molecular Underpinnings of Premalignant Oral Lesion Transformation into Head and Neck Cancer
$1,305,876Joe Nguyen · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Next generation T cell therapies for mutant KRAS solid tumors
$1,305,260Beatriz M. Carreno · University Of Pennsylvania · UG3 · FY2023 · CA
Natural Products Discovery and Characterization Through Network Collaborations
$1,304,841Lin Du · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1
$1,301,808Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2023 · CA
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$1,301,281Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Vaccine strategies for HIVAIDS
$1,300,408Jay A Berzofsky · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Conserved Element DNA Vaccine
$1,300,391Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
$1,299,370Andrea Califano · Columbia University Health Sciences · U01 · FY2020 · CA
Novel wearable rotating magnetic field therapy device targeting treatment of brain cancers
$1,296,385Ashok Gowda · Biotex, Inc. · R44 · FY2025 · CA
Immunotherapy to deplete key Treg subsets in solid tumors
$1,293,505Peter David Suzdak · Sonoval Llc · R44 · FY2024 · CA
FURTHER DEVELOPMENT OF IPSC-BASED VACCINE FOR COLON CANCER PREVENTION
$1,293,012Prema Robinson · University Of Tx Md Anderson Can Ctr · N01 · FY2023 · CA
Using Clinical Pharmacology Principles to Develop New Anticancer Therapies
$1,290,557William Douglas Figg · Division Of Clinical Sciences - Nci · ZIC · FY2021 · CA
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma
$1,286,039Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA